

## Virusure Announces the Collaboration with neotem Bioanalytics

Virusure GmbH – expert in pathogen safety testing, and neotem Bioanalytics – expert in Electron Microcopy Analysis, are joining forces to support the Biopharmaceutical Industry.

Vienna, Austria, 10<sup>th</sup> April 2024: **Virusure GmbH** ([www.virusure.com](http://www.virusure.com)), a leading contract research organization (CRO) providing pathogen safety testing services for the global biopharmaceutical industry, has announced a collaboration agreement with **neotem Bioanalytics**. With over 25 years of experience, neotem is renowned for its expertise in combining fast and precise transmission electron microscopy (TEM) analysis with the high-quality standards of Good Manufacturing Practice (GMP).

Virusure specializes in a comprehensive range of services encompassing virus and prion safety testing for biopharmaceutical products. These services include cell banking and characterization, in vivo biosafety studies, molecular and potency testing, GMP storage, sequencing, and Next-Generation Sequencing (NGS). These services are vital for biopharma and biotech companies focusing on biological products such as recombinant proteins, vaccines, human and animal-derived biological products, Advanced Therapy Medicinal Products (ATMPs), and cultured meat.

Dr. Andy Bailey, CEO, and co-founder of Virusure, expressed his enthusiasm about the collaboration, stating, *"We are delighted to announce this collaboration with neotem Bioanalytics, which resolves a bottleneck for high-quality and rapid transmission electron microscopy (TEM) analysis. We anticipate that this collaboration will assist our clients in improving timelines for pathogen safety testing."*

Angelika Spreitzhofer, Director of Quality Assurance at Virusure, highlighted the commitment to excellence, stating, *"I am proud that we could support neotem Bioanalytics in their efforts to enhance the quality system to achieve state-of-the-art GMP-compliant services for cell banks, virus banks, bulk harvests, and AAV testing via transmission electron microscopy (TEM) analysis."*

Dr. Dietrich Bäumer, Project Director at neotem, remarked, *"After the move into our new facility, the collaboration with Virusure marks the next step in our company development, benefiting from access to Virusure's wide global client base."*



# VIRUSURE

News Release

Ashley Stephen Layland, Project Director & Head of GMP Project Management at neotem, commented on the seamless collaboration between ViruSure and neotem, saying, *"It was a great pleasure to work closely together with the ViruSure team to establish rapid procedures for sample preparation and shipment to ensure TEM testing of bulk harvests, cell and virus banks, as well as gene therapy vectors within unbeatable timelines."*

### **About ViruSure GmbH**

Virusure is an established CRO offering a wide range of services in virus and prion safety testing, cell banking, cell bank characterization, in vivo biosafety studies, molecular and potency testing required by pharma and biotech companies. The company is committed to providing the highest level of quality, customer service, and regulatory compliance for pathogen safety testing. ViruSure's state-of-the-art facilities in Vienna, Austria, are certified to both GMP and GLP standards, supported by a risk-based quality management system to ensure cutting-edge service to the biopharmaceutical industry. [Further information on ViruSure can be found at www.virusure.com.](http://www.virusure.com)

### **neotem Bioanalytics-IIT GmbH**

neotem Bioanalytics focuses on GMP-compliant electron microscopy services for the biotech and pharmaceutical industry. As part of the "Institut für Innovationstransfer an der Universität Bielefeld GmbH" (IIT-GmbH), neotem has a combined experience of over 40 years in electron microscopy, complemented by expertise in cell culture technology, virology, and quality assurance. [Further information on neotem can be found at www.neotembio.com.](http://www.neotembio.com)

**Vienna-Bielefeld/16<sup>th</sup> of April 2024**

### **SOURCE**

Virusure GmbH

### **MEDIA CONTACT**

Virusure  
Dr. Ralf Klein  
Director Business Development  
+49 174 319 1173  
[Ralf\\_Klein@virusure.com](mailto:Ralf_Klein@virusure.com)